Datar Cancer Genetics is a world-leading multinational molecular oncology facility focused on innovative test solutions for cancer screening, diagnosis, and therapy guidance. We aim to help patients through the use of molecular oncology and personalized medicine.

Our innovative non-invasive blood-based test portfolio supports clinicians to select personalized therapies that will help improve patient outcomes. The US FDA has granted Datar Cancer Genetics 3 distinct Breakthrough Designations for liquid biopsies for Breast¹, Prostate², and Brain Tumors³. Our team of scientists, clinicians, advisors, and experts, based out of the UK, USA, Germany, and India, help advance our innovative technologies for better cancer management.

The Clinical Laboratory Improvement Amendments of 1988 (CLIA) has certified Datar Cancer Genetics clinical laboratory in Guildford, UK, and the College of American Pathologists (CAP) has granted it accreditation. It is equipped with state-of-the-art machines and analytics. The laboratory is registered with CQC and is currently an applicant with UKAS.

We provide a wide range of services in molecular genomics and Circulating Tumour Cell (CTC) analysis for cancer patients.

Our tests may be able to enhance your chances to win the battle against cancer through a smart combination of therapy guidance derived using multi-analyte analysis of the cancer cells.